Attached files

file filename
10-Q - HZNP Q3'18 10-Q - Horizon Therapeutics Public Ltd Cohznp-10q_20180930.htm
EX-32.1 - EX-32.1 - Horizon Therapeutics Public Ltd Cohznp-ex321_1057.htm
EX-31.2 - EX-31.2 - Horizon Therapeutics Public Ltd Cohznp-ex312_1059.htm
EX-31.1 - EX-31.1 - Horizon Therapeutics Public Ltd Cohznp-ex311_1060.htm
EX-10.3 - EX-10.3 - Horizon Therapeutics Public Ltd Coexhibit10_3.htm
EX-10.1 - EX-10.1 - Horizon Therapeutics Public Ltd Coexhibit10_1.htm
EX-4.14 - EX-4.14 - Horizon Therapeutics Public Ltd Coexhibit4_14.htm
EX-4.13 - EX-4.13 - Horizon Therapeutics Public Ltd Coexhibit4_13.htm
EX-4.12 - EX-4.12 - Horizon Therapeutics Public Ltd Coexhibit4_12.htm
EX-4.11 - EX-4.11 - Horizon Therapeutics Public Ltd Coexhibit4_11.htm
EX-4.10 - EX-4.10 - Horizon Therapeutics Public Ltd Coexhibit4_10.htm
EX-4.9 - EX-4.9 - Horizon Therapeutics Public Ltd Coexhibit4_9.htm
EX-4.8 - EX-4.8 - Horizon Therapeutics Public Ltd Coexhibit4_8.htm

 

Exhibit 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 18 U.S.C. Section 1350, I, Paul W. Hoelscher, Executive Vice President and Chief Financial Officer of Horizon Pharma PLC (the “Company”), certify to the best of my knowledge that:

 

1.

the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2018 (the “Report”), to which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

 

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 7, 2018

 

/s/ Paul W. Hoelscher

 

 

Paul W. Hoelscher

 

 

Executive Vice President, Chief Financial Officer

 

 

(Principal Financial Officer)

 

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.